R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 70.01
-0.63 (-0.89%)
At close: Jan 22, 2026
R&G PharmaStudies Revenue
R&G PharmaStudies had revenue of 227.71M CNY in the quarter ending September 30, 2025, with 24.48% growth. This brings the company's revenue in the last twelve months to 789.45M, up 4.06% year-over-year. In the year 2024, R&G PharmaStudies had annual revenue of 744.00M with 3.14% growth.
Revenue (ttm)
789.45M
Revenue Growth
+4.06%
P/S Ratio
8.44
Revenue / Employee
357.54K
Employees
2,208
Market Cap
6.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 744.00M | 22.63M | 3.14% |
| Dec 31, 2023 | 721.37M | 83.85M | 13.15% |
| Jan 1, 2023 | 637.52M | 29.09M | 4.78% |
| Jan 1, 2022 | 608.43M | 123.98M | 25.59% |
| Dec 31, 2020 | 484.45M | 59.00M | 13.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Novogene | 2.17B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| GemPharmatech | 752.70M |